uu.seUppsala University Publications
Change search
ReferencesLink to record
Permanent link

Direct link
Ginkgo biloba (EGb 761) in arteriosclerosis prophylaxis
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Pharmacy, Department of Pharmacy.
2007 (English)In: Wiener Medizinische Wochenschrift, ISSN 0043-5341, E-ISSN 1563-258X, Vol. 157, no 13-14, 288-294 p.Article in journal (Refereed) Published
Abstract [en]

The prevention or deceleration of atherogenesis is one of the most significant anti-aging objectives since this is a matter of avoidance of myocardial infarction and stroke. To approach this prophylactic aim, phytochemical nutrition counteracting peroxidation of blood lipids based on their scavenger qualities for reactive oxygen species (ROS) can possibly serve. For example, oxidized LDL particles are highly atherogenic. Against this background, we investigated in a pilot study the effect of Ginkgo biloba (EGb 761: Rökan®novo), the free oxygen radical scavenging properties of which are well-documented, on the atherosclerotic nanoplaque formation in cardiovascular high-risk patients. In eight patients who had undergone an aortocoronary bypass operation, the reduction of atherosclerotic nanoplaque formation amounted to 11.9 ± 2.5% (p < 0.0078) and of nanoplaque size to 24.4 ± 8.1% (p < 0.0234), respectively, after a 2-month therapy with Ginkgo biloba extract (EGb 761, 2 × 120 mg daily, Rökan®novo, Spitzner Arzneimittel, Ettlingen, Germany). Additionally, superoxide dismutase (SOD) activity was upregulated by 15.7 ± 7.0% (p < 0.0391), the quotient oxLDL/LDL lowered by 17.0 ± 5.5% (p < 0.0234) and lipoprotein(a) concentration decreased by 23.4 ± 7.9% (p < 0.0234) in the patients' blood after the 2-month medication regimen. The concentration of the vasodilating substances cAMP and cGMP was augmented by 37.5 ± 9.1% (p < 0.0078) and 27.7 ± 8.3% (p < 0.0156), respectively. A multimodal regression analysis reveals a basis for a mechanistic explanation of nanoplaque reduction under ginkgo treatment. The atherosclerosis inhibiting effect is due to an upregulation in the body's own radical scavenging enzymes and an attenuation of the risk factors oxLDL/LDL and Lp(a). Furthermore, the significant increase in the vasodilator cAMP and cGMP concentration powerfully supports the maintenance of an open bypass.

Place, publisher, year, edition, pages
2007. Vol. 157, no 13-14, 288-294 p.
Keyword [en]
Clinical trial, Ginkgo biloba, Arteriosclerosis prophylaxis, Ellipsometry, Lipoproteins, Nanoplaque formation and size, Proteoglycan receptor
National Category
Pharmaceutical Sciences
URN: urn:nbn:se:uu:diva-11398DOI: 10.1007/s10354-007-0426-6PubMedID: 17704974OAI: oai:DiVA.org:uu-11398DiVA: diva2:39167
Available from: 2007-09-12 Created: 2007-09-12 Last updated: 2010-04-20Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full textPubMedhttp://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=17704974&dopt=Citation

Search in DiVA

By author/editor
Malmsten, Martin
By organisation
Department of Pharmacy
In the same journal
Wiener Medizinische Wochenschrift
Pharmaceutical Sciences

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 165 hits
ReferencesLink to record
Permanent link

Direct link